使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and thank you for standing by. Welcome to the Q3 2026 Novo earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michael Novod, Head of Investor Relations. Please go ahead.
各位好,感謝您稍候。歡迎參加 Novo 2026 年第三季(Q3)財報電話會議。(接線員指示)請注意,今日會議將被錄音。現在我想把會議交給今天的講者——投資人關係主管 Michael Novod。請開始。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much, operator. Welcome to the Novo earnings call for the third quarter of 2026. My name is Michael Novod, and I'm the Head of Investor Relations at Novo. With me today, I have CEO, Mike Doustdar; EVP, US Operations; Jamey Millar; EVP, International Operations, Emil Kongshoej Larsen; EVP, Research and Development and Chief Scientific Officer, Martin Holst Lange; and Chief Financial Officer, Karsten Knudsen.
非常感謝,接線員。歡迎各位參加 Novo 2026 年第三季財報電話會議。我叫 Michael Novod,是 Novo 的投資人關係主管。今天與我一同出席的有:執行長 Mike Doustdar;美國營運執行副總裁 Jamey Millar;國際營運執行副總裁 Emil Kongshoej Larsen;研發執行副總裁兼首席科學長 Martin Holst Lange;以及財務長 Karsten Knudsen。
All speakers will be available for the Q&A session. Today's call is being webcasted live, and a recording will be made available on our website. The call is scheduled to last one hour. Next slide, please. The presentation is structured as outlined on slide 2.
所有講者都將出席問答環節。今天的電話會議將進行即時網路直播,並會在我們的網站提供錄影回放。本次會議預計為時一小時。請切到下一張投影片。簡報架構如第 2 張投影片所示。
(technical difficulty)
(技術問題)
Operator
Operator
Standby, as the speakers reconnect.
請稍候,講者正在重新連線。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
All right. Sorry for that. We'll try to start it from the getgo. On slide 3, we need to advise you that this call will contain forward-looking statements. These are subject to risks and uncertainties that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company announcement for the third quarter of 2026, and the slides prepared for this presentation.
好的。很抱歉。我們會從頭開始。在第 3 張投影片,我們需要提醒各位,本次電話會議將包含前瞻性陳述。這些陳述存在風險與不確定性,可能導致實際結果與預期有重大差異。關於風險因素的更多資訊,請參閱公司 2026 年第三季公告,以及本次簡報所準備的投影片。
With that, over to you, Mike, for an update on our 2030 ambitions.
接下來交給你,Mike,請你更新我們的 2030 年願景。
Maziar Doustdar - President and Chief Executive Officer
Maziar Doustdar - President and Chief Executive Officer
Thank you very much, Michael. Next slide, please. Back in September at our Capital Market Day, we set out our 2030 ambition to deliver mid-single-digit compounded annual sales growth in line with our industry peers from 2026 to 2030. Three commitments drove that ambition. We will grow and diversify our pipeline, we will drive sustainable growth, and we will deliver attractive returns to our shareholders. From this quarter onwards, we will hold ourselves accountable and report progress against each of them.
非常感謝,Michael。請切到下一張投影片。回到 9 月的資本市場日,我們提出 2030 年願景:在 2026 至 2030 年期間,實現與同業相當的中個位數複合年銷售成長。這項願景由三項承諾所驅動。我們將擴大並多元化我們的研發管線、推動永續成長,並為股東帶來具吸引力的報酬。自本季起,我們將對上述各項承諾負起責任,並回報各項進展。
On growing and diversifying our pipeline, we have initiated seven first human dose trials so far this year. In addition, we have 10 ongoing Phase III programs. Martin will cover the key pipeline developments about those later on. In terms of driving sustainable growth, we are now reaching around 48 million people with our diabetes and obesity treatments. This is 2 million more than just a year ago, especially within obesity, we are treating 5.6 million people, almost doubling during the past 12 months.
在擴大並多元化研發管線方面,今年迄今我們已啟動 7 項首次人體給藥試驗。此外,我們目前有 10 項正在進行的第三期(Phase III)計畫。稍後 Martin 將說明其中的關鍵管線進展。在推動永續成長方面,我們目前以糖尿病與肥胖症治療觸及約 4,800 萬人。這比一年前多了 200 萬人;尤其在肥胖症領域,我們正在治療 560 萬人,過去 12 個月幾乎翻倍。
Obesity sales grew by 22% in quarter three, supported by continued GLP-1 volume growth across geographies as well as the accelerated rollout of our innovative products, namely Wegovy Pill, and Wegovy Pill 7.2 milligram also known as Wegovy PillHD.
第三季肥胖症銷售成長 22%,主要受惠於各地區 GLP-1 銷量持續成長,以及我們創新產品加速導入,包括 Wegovy Pill,以及 7.2 毫克的 Wegovy Pill(亦稱 Wegovy PillHD)。
In terms of delivering attractive returns, we generated DKK32 billion in adjusted operating profit and more than DKK28 billion in free cash flow in Q3 2026. On the back of this strong quarter, we now expect adjusted sales growth of minus 2% to plus 2% and adjusted operating profit growth of minus 2% to plus 2%, both at CER. Karsten will speak to the updated guidance later. Please turn to the next slide.
在提供具吸引力的報酬方面,我們在 2026 年第三季創造了 320 億丹麥克朗(DKK)的調整後營業利益,以及超過 280 億丹麥克朗的自由現金流。在本季強勁表現的帶動下,我們目前預期調整後銷售成長為 -2% 至 +2%,調整後營業利益成長亦為 -2% 至 +2%,兩者皆以 CER(固定匯率)計。Karsten 稍後將說明更新後的財測指引。
The quarterly development clearly shows that we are at the growth recovery phase, and that is progressing well. Following adjusted sales decline of 2% in the fourth quarter of 2025 and 4% in the first quarter of 2026, we returned to 7% and 4% growth in the second and the third quarter, respectively. Additionally, we are happy to see that this quarter, both operating units are in growth territory again. Behind this is a clear turnaround in patient volumes. After a flat end to 2025 and a slight decline in the first quarter of 2026, we have now added 1.2 million patients in the second quarter and 1.3 million in the third, which is quite encouraging.
季度走勢清楚顯示我們正處於成長復甦階段,而且進展良好。在 2025 年第四季調整後銷售下滑 2%、2026 年第一季下滑 4% 之後,我們在第二季與第三季分別回到 7% 與 4% 的成長。此外,我們也很高興看到本季兩個營運單位都重新回到成長區間。其背後是病患量的明顯反轉。在 2025 年底持平、2026 年第一季小幅下滑之後,我們在第二季新增 120 萬名病患、第三季新增 130 萬名,這相當令人鼓舞。
What is promising is that growth comes from both obesity and diabetes. In obesity, we've added patients every single quarter, with 0.8 million in Q2 and 0.7 million in Q3. In diabetes, we have moved from losing 0.8 million patients in Q1 to adding 1 million patients in the past two quarters. In short, more patients are choosing Novo treatments, and we are reaching them across both of our core therapy areas.
令人振奮的是,成長同時來自肥胖症與糖尿病兩大領域。在肥胖症方面,我們每一季都在增加病患,第二季增加 80 萬、第三季增加 70 萬;在糖尿病方面,我們從第一季流失 80 萬名病患,轉為在過去兩季新增 100 萬名病患。簡而言之,更多病患選擇 Novo 的治療方案,而我們也在兩個核心治療領域中觸及到他們。
Next slide, please. In the third quarter, the adjusted sales growth was driven by both operating units. US operations grew 1%, while international operations grew 8%. Within IO, Region EUCAN remained the key growth area, delivering 18% growth. Across therapy areas, obesity continued to be the main growth driver.
請切到下一張投影片。第三季調整後銷售成長由兩個營運單位共同帶動。美國營運成長 1%,國際營運成長 8%。在國際營運(IO)中,EUCAN 區域仍是主要成長引擎,實現 18% 成長。在各治療領域中,肥胖症仍是主要成長動能。
And with that, I'll pass it to you, Emil, for a closer look at IO.
接下來我把時間交給你,Emil,請你更深入說明國際營運(IO)。
Emil Larsen - Executive Vice President - International Operations
Emil Larsen - Executive Vice President - International Operations
Thank you, Mike. Please turn to the next slide. Growth in IO continued to be driven by our GLP-1 portfolio in the third quarter. The total GLP-1 sales increasing by 8%. Obesity remains the key growth driver, delivering 24% growth, supported by continued volume uptick of Wegovy across regions.
謝謝你,Mike。請切到下一張投影片。第三季 IO 的成長仍主要由我們的 GLP-1 產品組合所帶動。GLP-1 總銷售成長 8%。肥胖症仍是關鍵成長動能,成長 24%,並受惠於 Wegovy 在各地區銷量持續上升。
From a regional perspective, EUCAN was the main growth contributor, with strong performance across both GLP-1 diabetes and obesity. However, performance in Canada was negatively impacted by lower realized prices following the loss of exclusivity for semaglutide. We continue to be the GLP-1 volume leader in IO with a market share of 54%. We are supporting this position with the rollout of Wegovy Pill, Wegovy Pill 7.2 milligram and Ozempic 2.0 milligram.
從區域角度來看,EUCAN 是主要成長貢獻者,在 GLP-1 糖尿病與肥胖症兩方面皆表現強勁。然而,加拿大的表現受到 semaglutide 失去獨家權後、實現價格下降的負面影響。我們在 IO 仍是 GLP-1 銷量領導者,市占率為 54%。我們透過推廣 Wegovy Pill、7.2 毫克 Wegovy Pill 以及 2.0 毫克 Ozempic 來鞏固此一地位。
Please turn to the next slide. We continue to expand our all obesity leadership across IO. The pill has now been launched in seven markets, most recently in Mexico, France, Spain and Poland, and with further launches planned during the fourth quarter. By first half of 2027, we now expect Wegovy Pill to be available in more than 20 markets. The market response in the UK and UAE is encouraging. While it is early days, we are seeing that Wegovy Pill is leading the oral obesity segment with around 90% market share in the UK and around 80% market share in the UAE in recent weeks.
請切到下一張投影片。我們持續在 IO 擴大整體肥胖症領導地位。該口服產品目前已在 7 個市場上市,最近上市的包括墨西哥、法國、西班牙與波蘭,並計畫在第四季進一步推出。我們目前預期至 2027 年上半年,Wegovy Pill 將可在超過 20 個市場取得。英國與阿聯的市場反應令人鼓舞。雖然仍在初期階段,但我們看到 Wegovy Pill 在英國以約 90% 市占率領先口服肥胖症市場區隔,且在阿聯近幾週約有 80% 市占率。
Six weeks into the launch in Germany, we've also seen solid uptake with approximately 100,000 packs sold mainly driven by GLP-1 naive patients, which suggests market expansion. While the UK market share development is encouraging, we're starting to see a normalization in the uptake, which naturally follows a bolus launch will pent-up demand.
在德國上市六週後,我們也看到穩健的採用情況,約售出 100,000 盒,主要由先前未使用 GLP-1 的病患所帶動,這顯示市場正在擴張。雖然英國市占率的發展令人鼓舞,但我們開始看到採用速度趨於正常化;這是一次集中式上市後、先前累積需求被釋放所自然帶來的結果。
Our focus is now to further build the obesity market. We'll do this by driving continued GLP-1 naive patient initiations, supporting patients throughout their treatment journey, ensuring clear switch guidance from injectables and expanding subscription options that can improve affordability and retention. Overall, these early launches reinforce our confidence that Wegovy Pill can reach a broader group of people living with obesity and strengthen our leadership across IO.
我們目前的重點是進一步打造肥胖市場。我們將透過推動持續的 GLP-1 未使用(naive)患者起始治療、在整個治療旅程中支持患者、提供從注射劑轉換的清晰指引,以及擴大可提升可負擔性與留存率的訂閱選項來達成。整體而言,這些早期上市進展強化了我們的信心:Wegovy 口服錠可觸及更廣泛的肥胖族群,並鞏固我們在 IO 領域的領導地位。
With that, over to Jamey for an update on the US.
接下來交給 Jamey,為大家更新美國市場的情況。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Thank you, Emil. Please turn to the next slide. The uptake of the Wegovy Pill has continued to outpace the oral competitor in Q3, with Wegovy Pill still capturing around 80% of NBRxs. This underpins the strong competitiveness of Wegovy Pill. Since launch, we have seen more than 8 million cumulative prescriptions, which remains the strongest US pharma launch by volume in over a decade outside of vaccines. We see a long runway for the pill in the US with current and incoming initiatives expected to drive more uptake into the new year.
謝謝你,Emil。請翻到下一張投影片。第三季 Wegovy 口服錠的採用持續超越口服競品,Wegovy 口服錠仍約占 NBRx 的 80%。這凸顯了 Wegovy 口服錠強勁的競爭力。自上市以來,我們已累計超過 800 萬張處方,按量計仍是十多年來(疫苗除外)美國最強勁的藥品上市表現。我們認為該口服錠在美國仍有很長的成長跑道,現有與即將推出的各項措施預期將在新的一年帶動更多採用。
In Q3, Wegovy Pill volumes grew around 20% versus Q2 and injectable Wegovy volumes grew around 10% sequentially, Q3 versus Q2. Part of the volume growth comes from the Bridge program, where we see encouraging uptake over the last few months. Further, we continue to see the Wegovy franchise leading new-to-brand prescriptions with more than 50% market share. The breadth of the franchise is central to our approach. Wegovy injectable, Wegovy high dose, and Wegovy Pill allow us to serve different patient preferences and treatment needs while building on the established profile of semaglutide.
第三季 Wegovy 口服錠的銷量較第二季成長約 20%,而注射型 Wegovy 的銷量亦較前一季(第三季相較第二季)成長約 10%。部分成長來自 Bridge 計畫,過去幾個月我們看到令人鼓舞的採用情況。此外,我們持續看到 Wegovy 系列在新品牌處方(new-to-brand prescriptions)方面領先,市占率超過 50%。產品組合的廣度是我們策略的核心。Wegovy 注射劑、Wegovy 高劑量與 Wegovy 口服錠,使我們能滿足不同患者偏好與治療需求,同時建立在 semaglutide 已確立的特性之上。
Please turn to the next slide. Turning to Diabetes. The transition from Rabelsis to Ozempic pill is now complete with new patients starting directly on the Ozempic brand. Since launch, weekly new-to-brand prescriptions for the oral franchise have more than doubled, demonstrating the strength of the Ozempic brand and the opportunity in the oral GLP-1 segment. Ozempic pill strengthens the franchise by giving patients and physicians an oral treatment option under a well-known and trusted brand.
請翻到下一張投影片。接著談糖尿病。從 Rabelsis 轉換至 Ozempic 口服錠的過渡現已完成,新患者已直接以 Ozempic 品牌開始治療。自上市以來,口服產品線每週的新品牌處方已超過倍增,展現 Ozempic 品牌的強勢,以及口服 GLP-1 區隔的機會。Ozempic 口服錠透過在知名且受信賴的品牌之下,為患者與醫師提供口服治療選項,進一步強化整體產品線。
It also creates opportunities to engage additional prescribers to compete more effectively across channels. Importantly, more than 60% of Ozempic pill new-to-brand prescriptions are from people who are new to GLP-1 treatment. This indicates that the launch is helping to expand the treated market rather than only switching patients within the class.
這也創造了機會,讓我們能接觸更多處方醫師,以在各通路更有效地競爭。重要的是,超過 60% 的 Ozempic 口服錠新品牌處方來自首次接受 GLP-1 治療的人群。這顯示此次上市有助於擴大接受治療的市場,而不僅僅是在同一類別內進行患者轉換。
We will continue to build awareness, support the transition across commercial channels and strengthen the combined Ozempic franchise. Over time, the oral and injectable offerings give us an opportunity to serve a broader range of people living with type 2 diabetes. We look forward to the potential FDA approval of Ozempic pill 25 milligrams by the end of the year, which will further strengthen our offering in diabetes with a highly competitive product profile.
我們將持續提升認知度、支持商業通路間的轉換,並強化整合後的 Ozempic 產品線。隨著時間推進,口服與注射的產品組合讓我們有機會服務更廣泛的第二型糖尿病患者。我們期待 Ozempic 口服錠 25 毫克在年底前獲得 FDA 潛在核准,這將以高度具競爭力的產品特性,進一步強化我們在糖尿病領域的產品供給。
With that, I hand it over to Martin.
接下來我把時間交給 Martin。
Martin Lange - Executive Vice President, Chief Scientific Officer, Research & Development
Martin Lange - Executive Vice President, Chief Scientific Officer, Research & Development
Thank you, Jamey. Next slide, please. During Q3, we continued to advance our pipeline. Starting with CagriSema, we have continued to build the evidence base ahead of the potential launch. In type two diabetes, we completed the six-week Phase III reimagine five trials, a robust head-to-head study enrolling over 1,000 patients comparing CagriSema 1 milligram of each component directly with Tirzepatide 5 milligram. This is a very relevant comparison as around 50% of global patients on Tirzepatide are on the 5-milligram dose or less, thus doing a more or less like real-world evidence study.
謝謝你,Jamey。請看下一張投影片。在第三季,我們持續推進研發管線。先從 CagriSema 開始,我們在潛在上市前持續累積證據基礎。在第二型糖尿病方面,我們完成了為期六週的第三期 reimagine 5 試驗,這是一項穩健的頭對頭研究,納入超過 1,000 名患者,直接比較 CagriSema(兩個成分各 1 毫克)與 Tirzepatide 5 毫克。這是一個非常具相關性的比較,因為全球約 50% 使用 Tirzepatide 的患者劑量為 5 毫克或以下,因此這更像是一項貼近真實世界證據的研究。
At 1 milligram of each component, CagriSema demonstrated superior weight loss of 12.4% compared with 9.1% for Tirzepatide, while delivering on PAN noninferior HbA1c reduction of around 1.7-percentage-points. The results from Reimagine 5 will supplement the regulatory submission for CagriSema in type 2 diabetes.
在兩個成分各 1 毫克的劑量下,CagriSema 的體重下降達 12.4%,優於 Tirzepatide 的 9.1%,同時在 PAN 非劣性(noninferior)HbA1c 降幅方面達成約 1.7 個百分點。Reimagine 5 的結果將補充 CagriSema 用於第二型糖尿病的法規申請資料。
In obesity, we completed Redefine 9, which also added evidence of the lower maintenance dose maintenance dose of CagriSema. In the trial CagriSema confirmed a highly attractive weight loss profile as the 1 milligram dose of each component demonstrated 21% weight loss at 68 weeks. As Novo expands its focus in women's health, as part of our broader consumer RX ambition, we are building our understanding of how CagriSema may address women's treatment needs across different stages of life.
在肥胖方面,我們完成了 Redefine 9,也為 CagriSema 較低維持劑量的維持治療提供了更多證據。在該試驗中,CagriSema 再次確認其極具吸引力的減重特性:兩個成分各 1 毫克的劑量在第 68 週達到 21% 的體重下降。隨著 Novo 在女性健康領域擴大投入,作為我們更廣泛的消費者處方藥(consumer RX)企圖的一部分,我們正在加深對 CagriSema 如何在不同人生階段滿足女性治療需求的理解。
Women represent a large proportion of people receiving obesity medicines. And the menopause transition is associated with change in body composition, including bone, increased abdominal fat and rise in cardiometabolic risk making effective weight management particularly relevant. Two recent post-hoc analysis of women in Redefine one may help address this evidence.
女性占接受肥胖藥物治療人群的很大比例。而更年期過渡期與身體組成改變相關,包括骨骼變化、腹部脂肪增加以及心代謝風險上升,使得有效的體重管理尤為重要。近期對 Redefine 1 中女性受試者所做的兩項事後(post-hoc)分析,可能有助於補足這方面的證據。
Overall, CagriSema was associated with an average weight loss of 25% in women. A separate analysis examining life stages largely classified using age-based criteria showed substantial weight loss across groups averaging 27-percentage-points, 25-percentage-points and 23-percentage-points, respectively, in pre-menopausal, perimenopausal and postmenopausal women. Taken together, these data broadened the evidence base of CagriSema and support the potential for a more individualized treatment approach, recognizing that patients have different needs and may not necessarily require the high stage.
整體而言,CagriSema 與女性平均 25% 的體重下降相關。另一項以年齡為主的標準來分類人生階段的分析顯示,各組皆有顯著減重:停經前、圍停經期與停經後女性的平均體重下降分別為 27 個百分點、25 個百分點與 23 個百分點。綜合來看,這些數據擴充了 CagriSema 的證據基礎,並支持更個人化的治療方式之潛力,因為患者需求各異,未必都需要高階段(high stage)。
Lastly, on CagriSema, we conducted a Phase II trial in people with type 2 diabetes and painful diabetic peripheral neuropathy. The study in CagriSema reduced pain by 2.4% -- sorry, 2.4 points from a baseline on the PI NRS score corresponding to approximately 38% reduction in pain on top of standard of care with more than 53% of patients reaching at least a 30% reduction in pain. Based on these very encouraging results, we plan to initiate Phase III trials in the neuropatic pain across the portfolio during 2027.
最後,關於 CagriSema,我們在第二型糖尿病合併疼痛性糖尿病周邊神經病變的人群中進行了一項第二期試驗。研究顯示,CagriSema 使 PI NRS 疼痛評分相較基線降低 2.4%——抱歉,是降低 2.4 分;在標準治療基礎上,相當於疼痛約降低 38%,且超過 53% 的患者達到至少 30% 的疼痛降低。基於這些非常令人鼓舞的結果,我們計畫在 2027 年於整體產品組合中啟動神經病理性疼痛的第三期試驗。
Turning back to the broader pipeline. We advanced oral zenagamtide into Phase III in the AMAZE-9 trial. Oral zenagamtide brings GLP-1 and amylin dual agonism into a differentiated unimolecular oral treatment. AMAZE-9 is linked to the extensive subcutaneous AMAZE program through exposure response modeling and bridging data to support the planned regulatory submission of both oral and subcutaneous. We expect AMAZE 9 to read out in 2028.
回到更廣泛的研發管線。我們已將口服 zenagamtide 推進至第三期,進入 AMAZE-9 試驗。口服 zenagamtide 將 GLP-1 與 amylin 的雙重致效(dual agonism)整合為具差異化的單分子口服治療。AMAZE-9 透過暴露量—反應(exposure response)模型與橋接數據,與大型皮下給藥 AMAZE 計畫相連結,以支持口服與皮下製劑的法規申請規劃。我們預期 AMAZE 9 將於 2028 年讀出結果。
Within blood and endocrine disorders, we are excited to potentially launch the in the European countries by the turn of this year, with a broader rollout in 2027. In the US, we're aiming to launch in the first half of 2027, pending regulatory decision.
在血液與內分泌疾病領域,我們對於有望在今年年底前後於歐洲國家上市感到振奮,並計畫於 2027 年更廣泛推廣。在美國,我們目標於 2027 年上半年上市,惟仍需視法規決定而定。
Next slide, please. Looking ahead, we are set to deliver important pipeline and regulatory milestones. Following the comprehensive pipeline update at our recent Capital Markets Day, I will focus today on a few key highlights.
請看下一張投影片。展望未來,我們將達成多項重要的研發管線與法規里程碑。在近期資本市場日(Capital Markets Day)提供全面的研發管線更新之後,今天我將聚焦於幾個關鍵重點。
Starting with obesity Amylin 355 recently advanced into Phase II with an expected readout in the second half of 2027. The trial investigates both subcutaneous and oral Amylin 355 in around 170 patients with overweight and obesity. For the oral formulation, we see the potential to leverage the Amylin biology to deliver a meaningful double-digit weight loss with potential fewer side effects.
先從肥胖症談起,Amylin 355 近期已推進至第二期臨床試驗,預計於 2027 年下半年讀出結果。該試驗在約 170 名過重與肥胖患者中,同時研究皮下注射與口服的 Amylin 355。就口服劑型而言,我們認為有機會運用 Amylin 的生物學機制,在副作用可能更少的情況下,帶來具意義的兩位數體重下降。
Continuing in the oral obesity space. We are anticipating the Phase I results of the oral ACSL5 inhibitor in the second half of 2027. ACSL5 inhibition is a non-GLP-1 oral small molecule approach with the potential to deliver double-digit weight loss alongside a differentiated tolerability profile and no need for dose titration. As a small molecule, it also offers the potential for high scalability. Cagrilintide with its amylin-based biology is expected to expand into a new patient pool and set a new standard for tolerability. Later this year, we expect to initiate Phase III of the high dose of cagrilintide. Further, we anticipate Phase III results of the renew -- sorry, RENEW 1 and 2 programs around mid-2027.
接著談口服肥胖領域。我們預期於 2027 年下半年取得口服 ACSL5 抑制劑的第一期結果。ACSL5 抑制是一種非 GLP-1 的口服小分子策略,有望在具差異化耐受性特徵且無需劑量滴定的情況下,帶來兩位數的體重下降。作為小分子藥物,它也具備高度可擴產的潛力。Cagrilintide 以其以 amylin 為基礎的生物學機制,預期可擴展至新的患者族群,並樹立耐受性的全新標準。今年稍晚,我們預計啟動高劑量 cagrilintide 的第三期臨床試驗。此外,我們預期於 2027 年年中左右取得 renew——抱歉,RENEW 1 與 2 計畫的第三期結果。
Lastly, with obesity, we anticipate Phase I/II results for both of our tri-agonists in the first half of 2027. These include UBT251 targets and the receptors of GLP-1, GIP and glucagon, and our internal triple molecule targeting GLP-1 GLP and amylin. Within liver disease, we submitted mass data for all semaglutide 25-milligram in the US. The submission is based on part 1 of the trial investigating semaglutide 2.4 milligram in mesh with moderate to advanced liver fibrosis. We're anticipating a US decision in the first half of 2027. In addition, we are still anticipating Phase III safety results from the Synchrony real world trial of in people living with and fibrosis stages F1 to F4. The trial's primary endpoint is safety and tolerability.
最後,在肥胖方面,我們預期於 2027 年上半年取得兩項三重致效劑的第一/二期結果。其中包括 UBT251,靶向 GLP-1、GIP 與升糖素受體,以及我們內部研發、靶向 GLP-1、GLP 與 amylin 的三重分子。在肝病方面,我們已在美國提交 semaglutide 25 毫克的 MASH 資料。該申請基於試驗第一部分,研究 semaglutide 2.4 毫克用於 MASH 且具中度至重度肝纖維化的患者。我們預期美國將於 2027 年上半年做出決定。此外,我們仍預期可取得 Synchrony 真實世界試驗的第三期安全性結果,該試驗納入 MASH 與纖維化分期 F1 至 F4 的患者。試驗的主要終點為安全性與耐受性。
With that, over to you, Karsten.
接下來交給你,Karsten。
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Thank you, Martin. Please turn to the next slide. In the third quarter of 2026, our adjusted sales increased by 4%, reaching DKK79.2 billion. This was driven by continued GLP-1 volume growth across US and IO, primarily in obesity.
謝謝你,Martin。請翻到下一張投影片。在 2026 年第三季,我們的調整後銷售額成長 4%,達到 792 億丹麥克朗。這主要由美國與國際營運(IO)GLP-1 銷量持續成長所帶動,主要來自肥胖領域。
Adjusted operating profit increased by 27% driven by GLP-1 sales growth and a favorable comparison base following approximately DKK9 billion of company-wide transformation costs recognized in the third quarter of 2025. This was partially offset by around DKK3.5 billion of onetime costs recognized in Q3 2026 within other operating expenses and R&D.
調整後營業利益成長 27%,受 GLP-1 銷售成長以及有利的比較基期所驅動;該比較基期源於 2025 年第三季認列約 90 億丹麥克朗的全公司轉型成本。但部分被 2026 年第三季於其他營業費用與研發中認列約 35 億丹麥克朗的一次性成本所抵銷。
For the first nine months of 2026, Novo has delivered better-than-expected sales and operating profits. As a result, we have raised our guidance again. The adjusted sales growth is now expected to be from minus 2% to plus 2% at CER. The improvement in the outlook is mainly driven by increased expectations for GLP-1 product sales. The outlook reflects expectations for sales growth within I/O and expectations for sales decline within US operations.
2026 年前九個月,Novo 的銷售與營業利益表現優於預期。因此,我們再次上調指引。以固定匯率(CER)計,調整後銷售成長率目前預期介於 -2% 至 +2%。展望改善主要由 GLP-1 產品銷售預期上調所帶動。該展望反映國際營運(I/O)銷售成長的預期,以及美國營運銷售下滑的預期。
In IO, the outlook is based on current growth trends, including continued volume penetration from GLP-1 treatments and market expansion. Novo continues to roll out the Wegovy product portfolio in more markets during 2026, including the Wegovy Pill. In US operations, the outlook is based on current prescription trends for the injectable TH1 portfolio. Lower realized prices linked to investments in market access amplified by the MFN agreement are assumed. Uptake related to the launch of Wegovy Pill is reflected in the outlook based on a range of assumptions.
在國際營運(IO)方面,展望基於目前的成長趨勢,包括 GLP-1 治療的持續滲透與市場擴張。Novo 於 2026 年持續在更多市場推出 Wegovy 產品組合,包括 Wegovy 口服錠。在美國營運方面,展望基於目前注射型 TH1 產品組合的處方趨勢。我們假設因市場准入投資而導致的已實現價格下降,並在 MFN 協議影響下被放大。與 Wegovy 口服錠上市相關的採用情況,已基於一系列假設納入展望。
Adjusted operating profit growth is now expected to be from minus 2% to plus 2% at constant exchange rates. The raised adjusted operating profit growth outlook reflects the improved sales outlook combined with targeted investments in current and future growth opportunities within R&D and commercial. This is partially funded by reinvestment of savings from the company-wide transformation program started in 2025 as well as further optimization initiatives and disciplined resource allocation. Our key modeling considerations for 2026 are shown on the slide including the improved free cash flow outlook now expected between DKK60 million and DKK70 billion. That was the outlook for 2026.
以固定匯率計,調整後營業利益成長率目前預期介於 -2% 至 +2%。調整後營業利益成長展望的上調,反映銷售展望改善,並結合在研發與商業端對當前與未來成長機會的精準投資。部分資金來源為 2025 年啟動的全公司轉型計畫所帶來的節省再投入,以及進一步的最佳化措施與嚴謹的資源配置。投影片中列示我們對 2026 年的關鍵建模考量,包括改善後的自由現金流展望,目前預期介於 600 億至 700 億丹麥克朗。以上為 2026 年展望。
Now over to you, Mike.
接下來交給你,Mike。
Maziar Doustdar - President and Chief Executive Officer
Maziar Doustdar - President and Chief Executive Officer
Thank you, Karsten. Next slide, please. As we closed yet another strong quarter above expectations and another guidance raise, I would also like us to take a moment and focus on what comes next. I've been at Novo for more than 30 years, and I can truthfully say that few things energize this organization like new launches. The coming period will bring two exciting potential launches FREHEMGO and CagriSema.
謝謝你,Karsten。請下一張投影片。在我們再次以優於預期的表現結束一個強勁季度、並再次上調指引之際,我也希望我們花點時間聚焦於接下來會發生什麼。我在 Novo 已超過 30 年,我可以真誠地說,幾乎沒有什麼能像新產品上市一樣讓這個組織充滿動能。接下來的一段期間,將帶來兩項令人振奮的潛在上市產品:FREHEMGO 與 CagriSema。
Let me start on the left side with FREHEMGO. People living with hemophilia have been asked to accept the trade-off between good protection and a heavy treatment burden for way too long. FREHEMGO is designed to remove that exact trade-off. The Frontier program demonstrated durable bleeding protections with the flexibility and the convenience of a once weekly once every second week or once-monthly injection in a simple, safe and easy-to-use device. That means more time living and less time managing a disease.
我先從左側的 FREHEMGO 談起。血友病患者長期以來被迫在良好保護與沉重治療負擔之間接受取捨,時間實在太久了。FREHEMGO 的設計目的,就是要消除這個取捨。Frontier 計畫證實其具持久的出血保護效果,並可透過簡單、安全且易用的裝置,提供每週一次、每兩週一次或每月一次注射的彈性與便利性。這代表患者有更多時間生活、較少時間管理疾病。
Our job now is to make switching from today's standard of care seamless, safe and the preferred choice for patients and doctors. That is exactly why I'm excited to roll out FREHEMGO globally during 2027 pending approval.
我們現在的任務,是讓從現行標準治療轉換的過程無縫、安全,並成為患者與醫師的首選。這也正是為什麼我對於在 2027 年(待核准後)於全球推動 FREHEMGO 的上市感到振奮。
Turning to CagriSema. Here, our job is simple. We need to get it to patients fast across channels. We are preparing as we speak. So we can go from approval to launch as quickly as possible. We will use Novo Care and our partners to reach consumers directly and make the customer experience as seamless and as simple as possible.
接著談 CagriSema。在這裡,我們的任務很簡單。我們需要透過各種通路,盡快讓患者用得到。我們正在同步準備。以便能在核准後盡可能快速地完成上市。我們將運用 Novo Care 與合作夥伴,直接觸及消費者,並讓客戶體驗盡可能無縫且簡單。
So to sum up, we have delivered a strong quarter, raised our guidance again and introduced a new strategy, culture and a brand for Novo. Across the organization, we are focusing on turning our innovation into successful launches that makes a meaningful difference for patients and society. I'm excited about what lies ahead for Novo and look forward to sharing our progress quarter after quarter.
總結來說,我們交出了一個強勁季度的成績,再次上調指引,並為 Novo 推出新的策略、文化與品牌。在整個組織中,我們正專注於把創新轉化為成功上市,為患者與社會帶來具意義的改變。我對 Novo 的未來感到振奮,並期待在每一季與各位分享我們的進展。
Next slide, please. Before we open for Q&A, I would like to say a few words about the change in our executive management. As announced earlier today, our CFO, Karsten, is leaving Novo after 27 years with the company. Throughout his career, Karsten has made a lasting contribution to Novo, most notably over the past nine years as CFO. He has been a trusted colleague and a highly respected leader known for his integrity and sound judgment and genuine commitment to patients and our people. On behalf of the entire Board of Directors, executive management and all of our employees, thank you, Karsten, for your many years of dedication, we wish you every success in the future.
請下一張投影片。在進入問答之前,我想先談幾句關於我們高階管理團隊的變動。如同今天稍早所宣布,我們的財務長 Karsten 在公司服務 27 年後將離開 Novo。在其職涯中,Karsten 對 Novo 做出了長遠且深刻的貢獻,尤其是在過去九年擔任財務長期間。他一直是值得信賴的同事,也是備受敬重的領導者,以正直、穩健判斷,以及對患者與同仁的真誠投入而聞名。我謹代表全體董事會、執行管理團隊以及所有員工,感謝你,Karsten,多年來的奉獻,並祝福你未來一切順利、持續成功。
At the same time, I am excited to welcome Luigi La Corte as our incoming CFO. Luigi joins us from Galderma as CFO, and he brings more than 30 years of international financial leadership experience across health care and consumer businesses. Karsten will remain with the company until end of this year to ensure a smooth transition and therefore, we turn to Q&A now.
同時,我也很高興歡迎 Luigi La Corte 出任我們的新任財務長(CFO)。Luigi 先前在 Galderma 擔任財務長加入我們,並在醫療保健與消費性業務領域擁有超過 30 年的國際財務領導經驗。Karsten 將留任至今年年底以確保順利交接,因此我們現在進入問答環節。
I would like -- before doing that, though, give the word to you, Karsten, for a few words.
不過在開始之前,我想先請你,Karsten,說幾句話。
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Thank you for your kind words, Mike. As Mike mentioned, this will be my last conference call as CFO at Novo. It has been a privilege to serve this company and to engage with all of you. Your questions, challenges and insights have consistently made us sharper and I have truly valued our open and constructive dialogue over the years. I leave with great confidence in our strategy, our strong financial foundation and above all, the people who drive Novo forward every day.
謝謝你的溢美之詞,Mike。正如 Mike 提到的,這將是我在 Novo 擔任財務長的最後一次電話會議。能為這家公司服務並與各位交流,是我的榮幸。各位的提問、挑戰與洞見一向讓我們更敏銳,我也非常珍惜多年來我們開放且具建設性的對話。我對我們的策略、穩健的財務基礎,尤其是每天推動 Novo 前進的人才,充滿信心地離開。
Thank you all for your trust and support over the years. And with that, let's open up for Q&A. Over to you, Michael.
感謝各位多年來的信任與支持。那麼,我們就開始問答環節。交給你了,Michael。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you, Karsten. Thank you, Mike. Next slide, please. With that, we're now ready for the Q&A, where I kindly ask all participants to limit her or himself to one or maximum two questions, including subquestions. Operator, we're now ready to take the first question.
謝謝你,Karsten。謝謝你,Mike。請到下一張投影片。接下來我們進入問答環節,我也懇請所有與會者每人限問一題,最多兩題(含追問)。接線生,我們準備好接第一個問題。
Operator
Operator
(Operator Instructions)
(接線生指示)
Peter Verdult, BNP Paribas.
BNP Paribas 的 Peter Verdult。
Peter Verdult - Analyst
Peter Verdult - Analyst
Pete Verdult from BNP Paribas. I rarely do this on a public conference call, but I will make an exception this time for Karsten to say thanks for the interactions over the years and best wishes on your next career chapter. On to the questions, two for you, Mike. Just firstly, on the upcoming CagriSema approval, is the probability of CagriSema having some sort of halo effect of a Wegovy-containing brand name high, medium or low?
我是 BNP Paribas 的 Pete Verdult。我很少在公開電話會議上這麼做,但這次我想為 Karsten 破例,感謝多年來的互動,並祝福你職涯下一章一切順利。回到問題,有兩個要問你,Mike。首先,關於即將到來的 CagriSema 核准,你認為 CagriSema 對含有 Wegovy 的品牌名稱產生某種「光環效應」的機率是高、中還是低?
And then secondly, I realize you're not going to provide any official guidance ahead of a CFO change, but a frequent question we get from investors is whether Novo can return to revenue growth in '27. I know there are many moving parts. I just wanted to keep the ties with you on your confidence that a positive growth number could feature in any guidance range you provide in February given what you're seeing across IO markets with a pill and post the Ozempic pill launch.
第二,我知道在財務長交接前你不會提供任何正式指引,但投資人常問我們的一個問題是:Novo 是否能在 2027 年恢復營收成長。我知道變數很多。我只是想了解,在你觀察到 IO 市場的口服藥進展,以及 Ozempic 口服藥上市後的情況下,你對於明年 2 月可能提供的指引區間中,是否可能出現正成長數字的信心如何。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much, Pete. So that was sort of 1.5 question. So both questions for Mike around first, CagriSema and sort of the halo. And then secondly, on close to '27, although we don't guide to '27.
非常感謝你,Pete。所以這大概算是 1.5 個問題。兩個問題都要問 Mike:第一是關於 CagriSema 以及所謂的光環效應。第二則是關於接近 2027 年的情況,雖然我們不對 2027 年提供指引。
Maziar Doustdar - President and Chief Executive Officer
Maziar Doustdar - President and Chief Executive Officer
So thanks, Pete. To answer your question on CagriSema, the brand name ends with Sema. So there's semaglutide in there, but there is more than Sema insight, which actually makes us incredibly excited. I think the introduction of Amylin as the first comp to do that, gives us a huge opportunity to build on the credibility that semaglutide has had for so many years and Wegovy, of course, brand, but go beyond that. I would say it's medium. It's not it's not high. It's not low, it's medium because we actually think that this is much, much more than semaglutide on the back of Amylin being mixed with it.
謝謝,Pete。回答你關於 CagriSema 的問題:品牌名稱以 Sema 結尾,所以其中含有 semaglutide(司美格魯肽),但它的內涵其實不只如此,這也讓我們非常興奮。我認為引入 Amylin(胰澱素)作為第一個這樣的複方成分,讓我們有很大的機會在 semaglutide 多年來建立的可信度,以及 Wegovy 的品牌基礎上再往前推進,並超越其本身。我會說是「中等」。不是高。也不是低,是中等,因為我們認為這在 Amylin 與其混合之後,遠遠不只是 semaglutide。
On the 2027 I think you are correct. As usual, we're not going to guide, but let me go out of my way and provide even more building blocks for next year. So maybe you can do your own math. I think the starting point, of course, is that we are nicely positioned in a growing GLP-1 market with a good runway and still quite a bit of unmet need as we have been able to show this year with our volume upticks, both on the injectable side as well as the PI.
至於 2027 年,我想你說得沒錯。照例我們不會提供指引,但我願意特別多提供一些明年的推算基礎。也許你可以自己做數學。我認為起點當然是:我們在成長中的 GLP-1 市場中處於良好位置,成長跑道充足,且仍有相當多未被滿足的需求;今年我們在注射劑以及 PI 方面的量能提升也證明了這點。
We start 2027 with the current runway and how we will end December. We just guided a midpoint of 0% for the first nine months. We will monitor how October, November and December will also look like and that's how really we build our own budget as well as, of course, the guidance to you. Now as usual, we'll have some pushes and some pulls, some pluses and minuses, let me give you three plus and three minus. The pluses for us next year is the continued Wegovy Pill uptake in US and IO. I don't foresee why should that completely change and how well we've done both in US and in IO does not change just because January comes after December.
我們進入 2027 年時,會以目前的跑道以及 12 月結束時的狀態為基礎。我們剛剛對前九個月給出的指引中位數是 0%。我們會觀察 10、11、12 月的表現,並以此來建立我們自己的預算,當然也包括對各位提供的指引。如同以往,會有推力與拉力、有利與不利因素。我給你三個正面與三個負面。明年的正面因素之一,是 Wegovy 口服藥在美國與 IO 的持續採用。我看不出為什麼這會完全改變;我們在美國與 IO 的表現不會因為 1 月接在 12 月之後就改變。
The other plus is we have seen a good uptick in US Bridge program. That program started mid this year. So you need to annualize it when you make your calculation for next year. Then the third positive element, I would say, is the two launches I just spoke about. CagriSema, FREHEMGO are two launches where we plan to introduce CagriSema in US, FREHEMGO in both sides of the Atlantic and hopefully, both of those will prove to be fantastic launches.
另一個正面因素是:我們看到美國 Bridge 計畫有不錯的增長。該計畫在今年年中啟動。因此你在推算明年時,需要把它年化納入計算。第三個正面因素,我會說是我剛提到的兩項上市。CagriSema 與 FREHEMGO 這兩項上市,我們計畫在美國推出 CagriSema,並在大西洋兩岸推出 FREHEMGO;希望兩者都能成為非常成功的上市。
On the negative side, I would say we've talked about the LOE this year in international operations and the early LOE markets. We have seen some of that already, more of it in Q3 than we saw in Q2. And next year, I would say, annualize that and see how that goes. Then the continued headwind that you currently see in China, minus 2% that we just showed, it's not going to go away just because Christmas turns into, again, a new year. And in addition, in China, we have loss of exclusivity next year, which we need to take into consideration.
負面因素方面,我會說我們今年已談到國際營運中的專利到期(LOE)以及較早發生 LOE 的市場。我們已經看到其中一部分,第三季比第二季更明顯。明年我會說,把這部分年化後再看其影響。接著是你目前在中國看到的持續逆風——我們剛展示的 -2%——不會因為聖誕節過了、進入新的一年就消失。此外,中國明年也會面臨專屬權到期(loss of exclusivity),這也需要納入考量。
And then last, maybe why not least, you see some favorable gross to net in 2026 that we should maybe under normal circumstances, not expect to the same degree next year. I don't know that. So those are the pluses and the minuses as far as I can go. And then we will, of course, guide with all of this in mind in 2027 at the full year announcement.
最後但同樣重要的是,你在 2026 年看到一些有利的毛額到淨額(gross-to-net)因素;在一般情況下,我們明年可能不應期待同等程度的有利影響。我也不確定。以上就是我能提供的正面與負面因素。當然,我們會在 2027 年全年業績公告時,綜合以上因素來提供指引。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
All right. Thank you, Mike, and to the brand name for CagriSema, that will come in due time. Next question, please.
好的。謝謝你,Mike。至於 CagriSema 的品牌名稱,會在適當時機公布。請下一個問題。
Operator
Operator
Sachin Jain, Bank of America.
美國銀行(Bank of America)的 Sachin Jain。
Sachin Jain - Analyst
Sachin Jain - Analyst
One for Jamey, one for Emil. For Jamey, on the US, Wegovy Pill script trends. Thanks for commenting to sequential growth. On your data, how much of that growth is the Bridge program? Are they just the bulk of Medicare and that's sequentially slurry, perhaps you could comment to that? And any color on why ex Medicare trends are flattish, if that's correct.
一題問 Jamey,一題問 Emil。先問 Jamey:關於美國 Wegovy 口服藥處方(script)趨勢。謝謝你提到環比成長。以你們的數據來看,這些成長有多少來自 Bridge 計畫?他們是否主要是 Medicare 的大量處方,而這在環比上可能較為混雜(slurry)?也許你可以評論一下。另外,如果我理解正確,為什麼非 Medicare 的趨勢看起來較為持平?能否提供一些說明。
For Emil, you commented on UK normalizing just after an updated pack number relative to the 65,000 per week you gave at the CMB. And perhaps I can just squeeze in a clarification from Mike. When you talk about current momentum continuing, I was a little bit confused in the answer to Pete's question, is the midpoint of guide 0% best proxy or the recent 2Q, 3Q growth rate of mid-single digits?
關於 Emil,你提到英國在更新的 pack 數量之後、相較於你在 CMB 提到的每週 65,000 份,正在正常化。也許我可以再補充一個來自 Mike 的釐清:當你談到目前動能延續時,我對你回答 Pete 的問題有點困惑——指引的中點 0% 是否是最佳代理指標,還是最近第 2 季、第 3 季中個位數成長率才是?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you, Sachin. So we'll stick with the two first questions. It's already beyond the number one. So first one question to Jamey on Bridge and then a question to Emil on uptake in IO.
謝謝你,Sachin。那我們先聚焦前兩個問題。這已經超過第一個問題的範圍了。所以先給 Jamey 一個關於 Bridge 的問題,接著給 Emil 一個關於 IO 採用率的問題。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes. Thanks, Sachin. Relative to Bridge, latest weekly data, we're seeing about 60,000 TRxs across injectable and oral in terms of Bridge. So the sequential growth of 20% in the quarter is largely been not exclusively Bridge volume. For the whole category, if you look May to October, and eliminate the contribution of the Bridge, the whole category is relatively flat, consistent with the seasonality that you see in that period outside of the consumer activation that we see in the wellness period that starts here in the fourth quarter and really peaks at the beginning of the year, with New Year's resolutions and a recommitment to health, if you will.
是的。謝謝,Sachin。就 Bridge 而言,從最新的每週數據來看,我們在注射與口服合計的 Bridge 方面約看到 60,000 筆 TRx。因此,本季 20% 的序列成長在很大程度上(但不完全)來自 Bridge 的量。若看整個類別,從 5 月到 10 月,並排除 Bridge 的貢獻,整體類別相對持平,這與你在該期間看到的季節性一致;而在第 4 季開始的健康旺季(wellness period)我們會看到消費者啟動活動,並在年初達到高峰,伴隨新年新希望與對健康的再次投入。
Emil Larsen - Executive Vice President - International Operations
Emil Larsen - Executive Vice President - International Operations
Yes. On the UK, we are still very pleased with 90% market share despite a competitor launch, of course, is very strong. In terms of how we fare versus what we shared at the Capital Markets Day, back then talked about 65,000 as weekly sales. Now we are probably around 60,000. So despite a competitor launch super strong and also with the seasonality at the moment being a bit low.
是的。就英國而言,即使競品上市,我們仍對 90% 的市占率非常滿意,當然這非常強勁。就我們相較於資本市場日(Capital Markets Day)所分享的表現而言,當時我們談到每週銷售 65,000。現在我們大概在 60,000 左右。因此,儘管競品上市非常強勢,加上目前季節性稍微偏低。
We move into November, December, that's typically peak where the online providers also invest heavily. I think what you should also take note of which we really are keenly focusing on is, of course, that this is not cannibalizing our injectable business. So that's perhaps what I'm most pleased about. This is really adding to our overall market share. So we are still faring more than 10-percentage-points higher than we did prior to the launch overall. So very positive.
進入 11 月、12 月,通常是高峰期,線上供應商也會加大投資。我認為你也應注意到、也是我們非常聚焦的一點:這並沒有侵蝕我們的注射劑業務。所以這可能是我最滿意的地方。這確實是在提升我們的整體市占。因此,我們目前的表現比上市前整體高出超過 10 個百分點。所以非常正面。
Now the focus, of course, is to build the segment, the class, that's probably up to us given our overall leadership with 90%. So we are focusing on subscription models, proving very successful for the providers to offer that focusing on clear switch guidance in the UK There are a lot of people with obesity who have tried the GLP-1. So if they've been on an injectable, we want to work with the private providers to ensure they start on the right dose. So there's a lot of the long haul of building this segment, but so far, we really see good synergistic effects between injectables and the pill, and that's perhaps what we are really celebrating at the moment.
當然,接下來的重點是把這個細分市場、這個藥物類別做大;以我們 90% 的整體領導地位來看,這大概取決於我們。因此我們正聚焦於訂閱制模式,供應商提供這類方案已證明非常成功;同時也聚焦於英國明確的轉換(switch)指引。英國有很多肥胖患者曾嘗試 GLP-1。若他們曾使用注射劑,我們希望與私人供應商合作,確保他們從正確劑量開始。因此,建立這個細分市場還有很多長期工作要做,但到目前為止,我們確實看到注射劑與口服藥之間良好的協同效應,而這也是我們此刻真正值得慶祝的。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very clear, Emil and Jamey. Next question, please.
謝謝,Emil 和 Jamey,講得很清楚。請下一題。
Operator
Operator
Simon Baker, Rothschild & Co Redburn.
Simon Baker,Rothschild & Co Redburn。
Simon Baker - Analyst
Simon Baker - Analyst
Let me echo Pete's comments earlier and wish you the robust for the future, Karsten. So on Wegovy, I wonder if you could give us an update on the impact of the subscription program. Is that affecting the capture rate of scripts that we're seeing because we kind of have to assume it's constant, but maybe it isn't.
我也呼應 Pete 先前的評論,並祝福你未來一切順利、Karsten。關於 Wegovy,我想請你更新一下訂閱制方案的影響。這是否正在影響我們看到的處方攫取率(capture rate)?因為我們大概會假設它是固定的,但也許並非如此。
And then secondly, on Wegovy high dose. You hopefully told us that it's 5% of total Wegovy Scripts in the US. But I wonder if you could give us any more color both within and outside the US on where that's coming from. Are these predominantly titrations up from Wegovy, switches from tirzepatide or patients starting afresh on that therapy. Any color on that would be really helpful.
第二個問題是關於 Wegovy 高劑量。你先前提到它在美國約占 Wegovy 總處方量的 5%。但我想請你提供更多細節,不論在美國境內或境外,這些處方主要來自哪裡。這些主要是從 Wegovy 逐步加量(titration)上去的?從 tirzepatide 轉換過來的?還是患者一開始就直接使用該療法?若能補充一些顏色(細節)會很有幫助。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much, Simon. So questions for Jamey to start with, and then maybe Emil can add a bit of color, at least on initial expectations.
非常感謝你,Simon。所以先請 Jamey 回答,然後也許 Emil 可以補充一些細節,至少談談初步預期。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes. So first question related to capture rate. The low capture relative low capture rates from IQVIA are not isolated simply to the subscription model. We have a much more extensive ecosystem of partners for Wegovy than our competitor, and those partners don't report to IQVIA in absolute terms. So we've consistently seeing a lower capture rate for Wegovy Pill than the competitive oral product. So not explained specifically by the subscription model.
好的。先回答關於攫取率的問題。IQVIA 顯示的相對較低攫取率,並不只是訂閱制模式所造成。我們在 Wegovy 的合作夥伴生態系比競品更廣泛,而這些合作夥伴在絕對數上並不向 IQVIA 回報。因此,我們一直看到 Wegovy Pill 的攫取率低於競爭對手的口服產品。所以這並非特別由訂閱制模式所解釋。
In terms of Wegovy high dose, the 7.2 milligram as you stated, about 20,000 prescriptions a week, 5% of total volume. If you look at the injectable business, both Lilly's and ours, about 15% of the TRxs are in the highest dose -- so there is still opportunity to move Wegovy HD further. 80%, your specific question, 80% of Wegovy high dose is titration from 2.4 milligrams. So those 20,000 scripts a week are scripts that otherwise would have been lost to the Wegovy franchise.
至於 Wegovy 高劑量,也就是你提到的 7.2 毫克,每週約 20,000 張處方,約占總量的 5%。如果看注射劑業務,不論是禮來或我們,大約有 15% 的 TRx 在最高劑量——因此 Wegovy HD 仍有進一步提升的空間。針對你的具體問題:Wegovy 高劑量中有 80% 來自於從 2.4 毫克逐步加量。因此,這每週 20,000 張處方,原本可能會從 Wegovy 產品線流失。
Emil Larsen - Executive Vice President - International Operations
Emil Larsen - Executive Vice President - International Operations
Yes. I mean, we talk a lot about the Wegovy Pill. But of course, year-to-date, it really is the Wegovy Injectables that has been driving our growth in IO with a very, very strong volume uptake and I would say, very disciplined in pricing where we've not given up. So just to give you a sense that volume growth year-to-date for Wegovy Injectable, been close to 70%, so very, very meaningful. That's, of course, why the high dose launches 7.2, we call the IO top priority.
是的。我的意思是,我們談了很多 Wegovy Pill。但當然,就今年迄今而言,真正推動我們在 IO 成長的是 Wegovy 注射劑,量的採用非常、非常強勁;而且我會說我們在定價上非常自律,沒有讓步。給你一個概念:今年迄今 Wegovy 注射劑的量成長接近 70%,非常、非常顯著。這當然也是為什麼 7.2 的高劑量上市,我們稱之為 IO 的最優先事項(top priority)。
We promised more than 30 launches by the end of the year, and we'll get there. We've had three so far. The one where we have the most meaningful experience from is the UK We launched back early June. And today, around 5% of our injectable patients have already started on a high dose. That's pretty good. And we, of course, keep supporting that.
我們承諾在年底前超過 30 個上市(launch),我們會達成。目前為止我們已經有三個。我們最有實質經驗的是英國:我們在 6 月初就上市了。而今天,大約有 5% 的注射劑患者已經開始使用高劑量。這相當不錯。而我們當然會持續支持。
We, over time, will also look at, of course, how can we facilitate patients who have maxed out on Wegovy Pill 25-milligram and also offer them an even more efficacious treatment with 7.2. So we give a lot of priority to this just launched in Germany, Poland and the rollout continues these very weeks.
隨著時間推進,我們也會評估,當然,如何協助已經在 Wegovy Pill 25 毫克達到上限的患者,並為他們提供以 7.2 帶來更高療效的治療選項。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Next question, please.
請下一題。
Operator
Operator
Martin Parkhoi, SEB.
Martin Parkhoi,SEB。
Martin Parkhoi - Analyst
Martin Parkhoi - Analyst
Martin Parkhoi for SEB. With the two questions. Just a question for Martin. With respect to expectations ahead of the Phase I/II readout in obesity of the two trial agonist. I'm not expecting you to give some kind of indication of where you see the weight loss.
我是 SEB 的 Martin Parkhoi。我有兩個問題。第一個問題想請教 Martin。關於雙重試驗致效劑(two trial agonist)在肥胖症的第 I/II 期讀出(readout)之前的預期。我不期待你提供你認為減重幅度會落在哪裡的任何指引。
I would more like to get you to get some expectations of how we should view the adverse event profile going out to this because there has been some noise when Novo Nordisk come out for Q2 -- sorry, with the Phase II results and high level of adverse events. How have the trials on the triagonist been set up with respect to this just to control expectations?
我更想請你談談,我們應該如何看待這項試驗的副作用事件(adverse event)輪廓,以便建立預期;因為在 Novo Nordisk 公布第 2 季——抱歉,是在公布第 II 期結果時——出現了副作用事件比例偏高的一些雜音。這些 triagonist 的試驗在設計上,針對這點是如何設定的,以便控制外界預期?
And then secondly, maybe that is for me, we can see in US that the Ozempic pill rebranding has been quite a success so far. Does that make any sense also to do that in some of the IO markets where Ozempic also is a high household name?
其次,或許就我而言,我們可以看到在美國,Ozempic 口服錠的重新品牌化到目前為止相當成功。在一些 IO 市場中,Ozempic 也是家喻戶曉的高知名度品牌,這樣做是否也有意義?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you, Martin. First question to Martin around triple reading out and then to Emil on the IO question.
謝謝你,Martin。第一個問題請 Martin 回答關於 triple 的讀出,接著 IO 的問題請 Emil 回答。
Martin Lange - Executive Vice President, Chief Scientific Officer, Research & Development
Martin Lange - Executive Vice President, Chief Scientific Officer, Research & Development
Yes. Thanks very much, Martin. So first of all, I just wanted to clarify where we typically see adverse events rates being captured in a very rigorous way is in Phase I because basically, we follow the patients very, very closely there. I think that is what you are referring to also because most of these trials are built with technicalities around how we capture the rate, but also how we want to drive the dose escalation in a meaningful way. So those are a little bit technical but also a little bit artificial.
是的。非常感謝你,Martin。首先,我想澄清一下:我們通常在哪裡會以非常嚴謹的方式收集不良事件發生率?那是在第一期(Phase I),因為基本上我們會非常、非常密切地追蹤受試者。我想你指的也是這一點,因為這些試驗大多在設計上包含一些技術細節,關於我們如何捕捉發生率,以及我們如何以有意義的方式推動劑量遞增。因此這些內容有點技術性,但也有點人工化。
What we will see readout of is proper Phase II trials. And here, we actually expect to see the, I would say, expected adverse event profile and tolerability profile of these two drugs. You've actually seen some readouts from Phase II, albeit in patients from UBT251. It looks very, very attractive with low adverse event rates and lower drawn rates.
我們將會看到讀出的是正式的第二期(Phase II)試驗。在這裡,我們其實預期會看到這兩種藥物的、我會說,符合預期的不良事件特徵與耐受性特徵。你其實已經看到一些第二期的讀出,雖然是在 UBT251 的病人中。看起來非常、非常有吸引力,不良事件發生率低,且停藥率也較低。
We cannot fully expect to see that in a global study, but our aspiration is to have adverse events in line with what we've seen with Wegovy and with other GLP-1 incretin-based therapies. And actually, for the triple, we potentially expect to see either in line and potentially even a more attractive safety profile and tolerability profile because the GIP component will come to its own right here.
我們無法完全期待在全球性研究中也看到同樣結果,但我們的目標是不良事件與我們在 Wegovy 以及其他以 GLP-1 腸泌素為基礎的療法所看到的水準一致。而且,對於 triple,我們可能預期安全性與耐受性特徵要嘛相當、甚至可能更具吸引力,因為 GIP 成分在這裡將能充分發揮其作用。
Emil Larsen - Executive Vice President - International Operations
Emil Larsen - Executive Vice President - International Operations
Yes. On Ozempic pill in IO, we have definitely taken note of the success that Jamey and team have delivered in the US. That's good inspiration. You'll be the first to hear if we end up concluding that it's a good product for IO as well. At the moment, our focus is the 2.0 launches.
是的。關於 IO 的 Ozempic 口服錠,我們確實注意到 Jamey 和團隊在美國所帶來的成功。這是很好的啟發。如果我們最後判定這也是一個適合 IO 的產品,你會是第一個知道的人。目前,我們的重點是 2.0 的上市推進。
We've come late to that NIO launched in 13 markets year-to-date, 20 by the end of the year. And so far, we have good results. We shared the results from Germany and the Netherlands, two early launch markets, but a number of other markets are also proving promising here. So that's our focus. That will already be enforced the Ozempic brand at a moment where for your building blocks for next year, we, of course, are facing increasing competition particularly in reimbursed markets across IO from a well-known competitor to you all. So it will be key to reinforce Ozempic, first with 2.0.
我們在這方面起步較晚;NIO 今年迄今已在 13 個市場上市,年底前將達到 20 個。到目前為止,我們有不錯的成果。我們分享了德國與荷蘭這兩個較早上市市場的結果,但其他多個市場也顯示出相當有前景。所以這是我們的重點。這也將在一個關鍵時點強化 Ozempic 品牌:就你們明年建模的基礎而言,我們當然正面臨競爭加劇,尤其是在 IO 各地的給付市場中,來自一位大家都很熟悉的競爭對手。因此,首先透過 2.0 來強化 Ozempic 將是關鍵。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much, Emil. Thank you very much, Martin. And then just to kind of ask again to limit yourself to one question. So as many as possible can get to ask the question. Next question, operator.
非常感謝你,Emil。非常感謝你,Martin。另外也再次提醒,請各位盡量只問一個問題,讓盡可能多的人都有機會提問。下一題,請接線員。
Operator
Operator
Matthew Weston, UBS.
Matthew Weston,瑞銀(UBS)。
Matthew Weston - Analyst
Matthew Weston - Analyst
I'm going to actually ask Sachin's question, Mike. Is the positive growth exit rate in the second half of 26%, the best proxy for '27? Or is the full year 0% average at the midpoint of guidance that you referenced earlier, the best baseline for next year? And if I can slip in one because I managed to get to slide 83. If roxifermin looks like you have no plans to launch until 2030 when you get the F4 data? Can you confirm no plans to go early with F3?
Mike,我其實要問 Sachin 的問題:下半年 26% 的正成長退出率(exit rate),是否是對 2027 年最好的代理指標?還是你先前提到、指引中點所對應的全年 0% 平均值,才是明年最好的基準?另外如果我可以再塞一題,因為我成功翻到第 83 頁投影片:如果 roxifermin 看起來你們在拿到 F4 數據之前都不打算在 2030 年前上市,你能否確認沒有計畫在 F3 就提前推進上市?
Maziar Doustdar - President and Chief Executive Officer
Maziar Doustdar - President and Chief Executive Officer
Yes. So the way that it works, we look at the totality of this year, we look at the pluses and the minuses that we had this year. And we look at quarter-by-quarter, frankly speaking, and then we look at the exact same thing for next year. I told you that on some notes, we see positive results for next year. I think the Bridge program is a great example of that. We've had half of that. We're happy with it. Let's do that for the full year next year.
是的。運作方式是這樣:我們會看今年的整體情況,檢視今年的利多與利空。坦白說,我們也會逐季來看,然後明年也用同樣的方法檢視。我跟你說過,在某些項目上,我們看到明年會有正面結果。我認為 Bridge 計畫就是一個很好的例子。我們今年只做了一半。我們對結果很滿意。明年我們就把它做滿全年。
On the other hand, LOE in international operations is exactly the opposite of that. So I would not give you numbers again today, we're not guiding. But what I do tell you is that right now, we've guided 0% midterm for the first nine years -- nine months. So that's basically how we're going to look at this going forward. On the question, we have to follow the data. We will look at the data for F2, F3, F4, and then make a decision. I don't know if Martin wants to add any more to that.
另一方面,國際營運(international operations)的 LOE(專利到期/獨占期到期)則完全相反。所以我今天不會再給你數字,我們目前沒有提供指引。但我能告訴你的是:就目前而言,我們對前九個月的指引中點是 0%。因此,這基本上就是我們未來看待這件事的方式。至於你問的那個問題,我們必須依據數據來走。我們會看 F2、F3、F4 的數據,然後再做決定。我不知道 Martin 是否想補充。
Martin Lange - Executive Vice President, Chief Scientific Officer, Research & Development
Martin Lange - Executive Vice President, Chief Scientific Officer, Research & Development
I think it's important to call out that is where we see the big unmet need. We already have a drug on the market for F2 and F3. It's called Wegovy. And therefore, to Mike's point, will be guided by the data as we see them.
我認為重要的是要指出:那正是我們看到重大未被滿足需求(unmet need)的地方。我們在 F2 和 F3 已經有一個上市藥物,叫做 Wegovy。因此,如同 Mike 所說,我們會依據我們所看到的數據來決定。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you, Matthew. Next question, please.
謝謝你,Matthew。下一題,謝謝。
Operator
Operator
Richard Vosser, JPMorgan.
Richard Vosser,摩根大通(JPMorgan)。
Richard Vosser - Analyst
Richard Vosser - Analyst
One on Ozempic, please. Maybe you could talk about the underlying price dynamics this quarter throughout this year, whether there's any impact from lower 340B rebates going through to better prices? And how you're thinking about that into next year? I noticed you didn't mention IRA next year. I know we talked about that last quarter, but is that still a headwind in terms of price? Or are there price benefits that offset that next year?
請問一題關於 Ozempic。你能否談談本季以及今年以來的底層價格動態?是否有任何來自較低 340B 回扣、進而反映為較佳價格的影響?以及你們如何看待這對明年的影響?我注意到你們沒有提到明年的 IRA。我知道我們上季談過,但就價格而言,這是否仍是逆風?或者明年是否有價格面的利多可以抵消?
And then the second question, maybe you could just talk about that oral rollout. I think 12 or so incremental markets in the first half of '27. Maybe you could talk about the relative opportunity of those markets relative to the UK and how early days, France, Poland, Mexico, et cetera, are going and their relative opportunity?
第二個問題,你能否談談口服劑型的推廣進度?我想在 2027 年上半年會新增大約 12 個市場。你能否談談這些市場相對於英國的機會大小,以及法國、波蘭、墨西哥等市場在早期進展如何與其相對機會?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you, Richard. The first question to Jamey and then the second question to Emil.
謝謝你,Richard。第一個問題請 Jamey 回答,第二個問題請 Emil 回答。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes. Thanks for the question, Richard, on Ozempic gross to net trend. So as we've guided before, suggested the 10% to 15% price erosion on an annual basis is the way to think about it. There's so much fluctuation variability quarter-to-quarter. Obviously, in the quarter, we saw significantly better range than the 10% to 15%. But year-to-date and over a 12-month period, we still feel 10% to 15% is reasonable. The payer pressure on net prices in the type 2 diabetes category remain and will continue. So that's our best judgment there.
是的,謝謝你的問題,Richard,關於 Ozempic 的 gross-to-net 趨勢。如同我們先前所指引的,我們建議以每年 10% 到 15% 的價格侵蝕來理解。季度之間的波動變異非常大。很明顯地,在本季我們看到的區間顯著優於 10% 到 15%。但以年初至今以及 12 個月期間來看,我們仍認為 10% 到 15% 是合理的。在第二型糖尿病類別中,付款方對淨價的壓力仍然存在且會持續。因此,這是我們在此的最佳判斷。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Emil?
Emil?
Emil Larsen - Executive Vice President - International Operations
Emil Larsen - Executive Vice President - International Operations
Yes. On the rollout in IO, of course, I'm very pleased with our manufacturing colleagues because they keep upping the output. And you noticed at Capital Markets Day, we promised 20 markets by end of next year. Now we promised by end of first half. So that's, of course, incredibly positive.
是的。關於在 IO 的推廣進展,當然,我對我們製造端的同仁非常滿意,因為他們持續提高產出。而且你也注意到在資本市場日上,我們承諾在明年年底前覆蓋 20 個市場。現在我們承諾在上半年末就達成。所以這當然是非常正面的。
We also back then shared that this would correspond to two-thirds of the market potential. So we reached that earlier, of course. And then across the markets, I've learned to be rather humble predicting potential in this space. But of course, you could say markets with a low penetration and a propensity to tablets such as Mexico. That is a relatively speaking, bigger market expansion opportunity versus the Danish market, for instance, that's more mature with a 10% treatment rate. So there's something about where are we on treatment rates, what is the propensity to online and tablets altogether. But overall, of course, we see it as a hugely important opportunity.
我們當時也分享過,這將對應於約三分之二的市場潛力。所以我們當然更早就達到了。此外,跨不同市場,我也學會在預測這個領域的潛力時要更謙遜一些。但當然,你可以說像墨西哥這類滲透率較低、且對口服錠劑接受度較高的市場。相較之下,這類市場的擴張機會會比例如丹麥市場更大;丹麥市場更成熟,治療率約 10%。因此,關鍵在於我們目前的治療率處於什麼位置、以及對線上與口服錠劑整體的接受度如何。但總體而言,我們當然把它視為一個極其重要的機會。
And in the early innings, it will still be Europe driving the majority. Then of course, we'll see, and that's what we will learn next year. In markets that have gone LOE what does the fact that this would be a premium offering from a pricing perspective means to the volumes we can secure there. And we'll keep you posted on those learnings as we move into next year.
而在早期階段,仍將由歐洲帶動大部分成長。接著當然,我們會觀察——這也是我們明年將學到的。在已進入 LOE(專利到期後競爭)狀態的市場中,若從定價角度看這會是一項溢價產品,這對我們能取得的銷量意味著什麼。隨著我們進入明年,我們也會把這些學習結果持續向各位更新。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Next question, please.
下一題,謝謝。
Operator
Operator
Michael Leuchten, Jefferies.
Michael Leuchten,Jefferies。
Michael Leuchten - Analyst
Michael Leuchten - Analyst
I'll stick to one and Karsten, thank you so much for the interactions over the years. A question is just a follow-up on your commentary, Jamey, on the Bridge contribution to the franchise. So do I understand correctly that without Bridge you wouldn't have grown the GLP-1 franchise? And what does that mean as Bridge starts to annualize?
我只問一題;Karsten,也非常感謝你這些年來的互動。我的問題是延伸追問你剛才的評論,Jamey,關於 Bridge 對該產品組合(franchise)的貢獻。所以我是否可以理解為:如果沒有 Bridge,你們的 GLP-1 產品組合就不會成長?而當 Bridge 開始進入年化比較基期時,這代表什麼?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much, Michael. Question to Jamey on Bridge in the US.
非常感謝你,Michael。這題請 Jamey 回答,關於美國的 Bridge。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes. Without the Bridge contribution, there is less growth in the 20% sequential growth that we talked about. Bridge is definitely creating an inflection in the category and without Bridge, the AOM category, not just Novo, but the category looks relatively flat in the May to October time frame, reflecting the seasonality.
是的。若沒有 Bridge 的貢獻,我們所談到的 20% 季比成長中,成長幅度會比較小。Bridge 的確正在為這個品類帶來一個拐點;如果沒有 Bridge,AOM 品類——不只是 Novo,而是整個品類——在 5 月到 10 月期間看起來相對持平,反映出季節性因素。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Next question, please.
下一題,謝謝。
Operator
Operator
James Quigley, Goldman Sachs.
James Quigley,Goldman Sachs。
James Quigley - Analyst
James Quigley - Analyst
Also thank you, Karsten, for your help over the years and better luck in the future. Maybe one for you, Karsten. So on the upgraded guidance range of -- for 2026, the implied range for Q4 is super wide. I think it DKK12 billion swing. So what are the key factors side there. And then as we look into next year with the gross to net is quite high this year, how should we treat that as we're thinking for '27? Is that an unwind? Or is that a new base from which sales need to grow from?
也謝謝你,Karsten,這些年來的協助,祝你未來一切順利。我可能有一題想問你,Karsten。關於你們上調後的 2026 年指引區間,隱含的第四季區間非常寬。我想大概有 120 億丹麥克朗的擺動。所以主要的驅動因素是什麼?另外,展望明年,今年的 gross-to-net 相當高,我們在思考 2027 年時應該如何看待?這會回轉(unwind)嗎?還是這會成為新的基準,之後銷售要在此基礎上成長?
And then secondly, quickly for Jamey on the CagriSema launch in the US. As you prepare for the launch, how are you thinking about market segmentation which patients or consumers will the initial marketing campaign target? Sounded a little like older women from Martin's comments, but will you have sufficient data for the launch here? And what is the best analog we should look at as we start to model the launch.
第二題,快速問 Jamey,關於 CagriSema 在美國的上市。當你們準備上市時,你們如何思考市場區隔——初期行銷活動會鎖定哪些病患或消費者?從 Martin 的評論聽起來有點像是年長女性,但你們在上市時會有足夠的數據嗎?而我們在開始建模這次上市時,應該參考的最佳類比案例是什麼?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much. First question to Karsten on a year to go in 2026, and then over to Jamey on.
非常感謝。第一題先請 Karsten 回答,關於 2026 年還有一段時間的展望,然後再交給 Jamey。
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
James, thanks for the nice words. And specifically to your question on implied growth and guidance ranges then I'll just say, as to the guidance ranges, the breadth we have here in Q3 is completely customary at this point in time. And the reason why we have this breadth is that we are navigating a rapidly growing category with a certain degree of volatility. So that's why we keep it a little bit wider compared to the heydays when it was pure insulin and extremely linear. So that's really the reason there.
James,謝謝你的好意。針對你問到的隱含成長與指引區間,我想說的是:就指引區間而言,我們在此時點於 Q3 給出的寬度是完全符合慣例的。之所以會有這樣的寬度,是因為我們正在應對一個快速成長、且具有一定波動性的品類。因此,相較於過去以胰島素為主、走勢非常線性的黃金時期,我們會把區間保留得稍微寬一些。這就是主要原因。
And in terms of implied growth, it's important to note that while we are growing 2% year-to-date, and we have a midpoint of zero, then we do have a tough comparator in the fourth quarter due to US gross-to-net last year of DKK3 billion in the fourth quarter. And then LOE in mainland Canada, Emil spoke to also having a bigger impact in the fourth quarter compared to the first nine months. So those are really the two biggest ticket items impacting the fourth quarter and the implied growth there.
至於隱含成長,需要注意的是:雖然我們年初至今成長 2%,而指引中位數是 0%,但第四季的比較基期很硬,因為去年第四季美國的 gross-to-net 有 30 億丹麥克朗。此外,加拿大本土市場的 LOE(專利到期後競爭),Emil 也提到,相較於前九個月,對第四季的影響更大。所以,影響第四季與其隱含成長的兩個最大項目,基本上就是這兩點。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
For you, Jamey?
Jamey,交給你?
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes. And as for segmentation, it's absolutely the right question, but you'll understand and appreciate if I don't graphically describe our launch strategy. But that said, I'll make 2 points. one, super excited about CagriSema and expanding the optionality for physicians and for patients. Increasingly, as more competitors come into the category having a portfolio of singles doublet, triplets over time is going to be really important from a competitive standpoint.
是的。關於市場區隔,這確實是個非常正確的問題,但也請你理解,我不便非常具體地描述我們的上市策略。不過我想提出兩點。第一,我們對 CagriSema 非常興奮,因為它能為醫師與病患提供更多選擇。隨著越來越多競爭者進入這個品類,從競爭角度來看,擁有單方、雙方,並隨時間推進到三方的產品組合,將會非常重要。
And as you described, as the information data emerges on CagriSema, there is a nice profile that is emerging in terms of the efficacy of the product even at lower doses, as Martin described, and the patient population perimenopausal women where we recently announced the 25% weight loss seen in the study. So thank you for your question, and we're super excited about the launch coming up.
第二,如你所描述,隨著 CagriSema 的資訊與數據逐步揭露,產品特性正在形成一個不錯的輪廓:即使在較低劑量下也具有效力,如 Martin 所說;此外,在圍更年期女性族群中,我們近期公布研究中觀察到 25% 的體重下降。所以謝謝你的提問,我們也非常期待即將到來的上市。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Next question, please.
下一題,謝謝。
Operator
Operator
Martin Brenoe, Nordea.
Martin Brenoe,Nordea。
Martin Brenoe - Analyst
Martin Brenoe - Analyst
I just have two left, please. First question would be whether you can provide a bit of color on how you see the price dynamics heading into 2027. Just what the main building blocks that we need to be aware of when we do our modeling?
我還有兩題,謝謝。第一題是,你們能否補充一些看法,說明你們如何看待邁向 2027 年的價格動態?也就是說,在我們做模型時,需要注意的主要構成要素有哪些?
And second question, is on the Wegovy Pill. Now you're committing to rolling out the Wegovy Pill a bit faster than what you indicated just less than two months ago. Can you just help us understand what's been the main driver behind this assumption and whether you still see some upside to this accelerated rollout that you are now promising here?
第二題是關於 Wegovy 口服錠劑。你們現在承諾推進 Wegovy 口服錠劑的上市速度,比不到兩個月前所指引的更快。能否協助我們理解,這個假設背後的主要驅動因素是什麼?以及你們是否仍看到一些上行空間,來支持你們現在承諾的這個加速推廣?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thank you very much, Martin. So some high-level comments from Jamey on the US and then over to Emil on accelerating Wegovy Pill in IO.
非常感謝你,Martin。先請 Jamey 就美國市場做一些高層次的評論,然後再請 Emil 談 IO 中 Wegovy 口服錠劑加速推進的部分。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
I apologize if a bit repetitive. But on the Ozempic side, as we've suggested that 10 to 15 price degradation trend is kind of our experience in what we would suggest not guiding, but that trend continues. And then on the Wegovy side, we've again seeing 30%, 35% in the quarter, again, with the variability a little on the high end, but we expect that or a little better moving forward. Just to clean up maybe one question that was asked before that I missed and has been answered previously. Because of the Ozempic trend, NFP pricing, we don't expect to have an incremental negative consequence because that's been the trajectory we've been on. So someone asked that before, and I didn't cover it.
如果有點重複我先致歉。就 Ozempic 而言,如我們先前所提,我們的經驗是價格下滑趨勢大約在 10% 到 15%;我們不是在做指引,但這個趨勢仍在延續。而在 Wegovy 方面,我們同樣看到本季約 30%、35% 的表現;雖然波動性在高端略大一些,但我們預期往後會維持這樣的水準,或略有改善。另外我想補充釐清一個先前有人問、我當時漏答、但之前其實已回答過的問題。由於 Ozempic 的趨勢與 NFP 定價,我們不預期會有額外的負面影響,因為這一直是我們所處的軌跡。所以先前有人問到這點,我當時沒有涵蓋到。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thanks, Jamey.
謝謝你,Jamey。
Emil Larsen - Executive Vice President - International Operations
Emil Larsen - Executive Vice President - International Operations
Yes, on the acceleration, it is really back to, of course, manufacturing stepping up, producing above what the lines are expected to be able to deliver. I've been visiting myself to chair and the teams, and they're really doing a great job working 24/7.
是的,關於加速這件事,確實回到——當然——製造端正在加緊提升產能,產出已高於產線原本預期能交付的水準。我自己也去現場與主管及團隊一起看過,他們真的做得非常好,24/7 不間斷地運作。
Another aspect is regulatory. We've actually taken some learnings of how we also rolled out. Wegovy injectable very quickly, working with multi-country packs, et cetera. So great work to also optimize. That simply means you can have launch batches, serving more countries and hence, speed up productivity in manufacturing.
另一個面向是法規。我們其實也從先前的推進方式中學到一些經驗。例如 Wegovy 注射劑能非常快速地推出,並搭配多國包裝等作法。因此在最佳化方面也做得很好。這基本上意味著你可以用同一批上市批次供應更多國家,因而提升製造端的生產效率與速度。
So that's helped. You saw maybe also the breaking news of the day, Australia. We got approval also great local regulatory work, so another front loading there. So it's a combination of manufacturing, regulatory work and really close collaboration.
所以這確實有所幫助。你們今天可能也看到突發消息:澳洲。我們也獲得核准,當地法規團隊做得非常出色,因此又多了一個可以提前布局的面向。所以這是製造、法規工作以及非常緊密協作的綜合結果。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Next question please.
下一題,謝謝。
Operator
Operator
Seamus Fernandez, Guggenheim Securities.
Seamus Fernandez,Guggenheim Securities。
Seamus Fernandez - Equity Analyst
Seamus Fernandez - Equity Analyst
So my question is just kind of going back to that -- the comment about the sequential growth from March basically being flat and the contribution of the Medicare Bridge program being the main accelerator. That speaks to, I think, to some degree, a cautionary tail for payers potentially lowering the price or helping to lower the price of treatment. I guess the big question is, how do you get commercial pay to really step in and start to reveal the benefits, the medical benefits that we all know, GLP-1s actually have given several appear to have pulled back from supporting the obesity opportunity.
我的問題是回到剛才——關於從 3 月開始的逐月成長基本持平,以及 Medicare Bridge 計畫的貢獻是主要加速因素的評論。我認為這在某種程度上反映出一個警示性的尾端風險:付款方可能會傾向壓低價格或協助降低治療價格。我想最大的問題是,你們要如何讓商業保險付款方真正介入並開始展現我們都知道的好處——GLP-1 類藥物確實帶來醫療效益——但看起來有好幾家似乎已經縮手,不再支持肥胖症這個機會?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thanks, Seamus. So to Jamey, on that question regarding dynamics in the US payer market.
謝謝你,Seamus。那麼,Jamey,關於美國付款方市場動態的這個問題。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes. It's a great question. It's a simple question with a difficult answer. But the reticence on behalf of the downstream payers, employers, government, private payers is increasingly about the volume concern side of the equation. Price keeps coming down, net prices, competition is working in that sense.
是的,這是個很好的問題。這是一個簡單的問題,但答案很難。不過,下游付款方——雇主、政府、民間付款方——之所以愈來愈猶豫,主要是因為等式另一端的「用量」疑慮。價格持續下降,淨價也在下降,競爭在這方面確實發揮作用。
Our list prices will also come down 1127 as previously announced. But how payers control the cost trend that they see, which is the price times volume equation, is the challenge. We're engaged daily with employers, third-party payers, PBMs on their behalf to try and manage the volume in a unique and different way so that they can manage the cost trend.
我們的標價也將如先前宣布的那樣在 1127 下調。但付款方要如何控制他們所看到的成本趨勢——也就是「價格 × 用量」這個等式——才是挑戰。我們每天都與雇主、第三方付款方、以及代表他們的 PBM 密切合作,嘗試以獨特且不同的方式管理用量,讓他們能夠管理成本趨勢。
But you're right, whether it's Pepsi, Starbucks, other large employers, when they see the cost trend, they move against despite the clinical and economic benefit long term of medical cost offsets that have been demonstrated in the market. So we continue to fight that battle and seek greater access for the category, by the way, again, not unique to Novo. This is a categorical issue and opportunity that we're working on.
但你說得對,不論是 Pepsi、Starbucks 或其他大型雇主,當他們看到成本趨勢時,即使市場上已經證明長期在臨床與經濟面(醫療成本抵減)都有好處,他們仍會採取反向動作。因此我們會持續投入這場戰役,爭取這個類別更大的可近性;順帶一提,這也不僅是 Novo 的問題,這是整個類別的議題與機會,我們正在共同努力。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Right. Thank you very much. Last question, please.
好的。非常感謝。請最後一題。
Operator
Operator
Kerry Holford, Berenberg.
Kerry Holford,Berenberg。
Kerry Holford - Analyst
Kerry Holford - Analyst
And thank you again also to Karsten for the many years of interactions. I won't finish again on Bridge. Just linking to that question in a way with regard to commercial options as it does now settle up to the US returns today, Jamey, I wonder if you can comment on your expectations on the Medicare Bridge, let's say, the Medicare coverage extend beyond the end of Bridge, which I know that you come to an end at the end of next year, if that appetite is not there to provide access more broadly, how do you see it playing out within the Medicare channel?
也再次感謝 Karsten 多年來的交流互動。我不會再重複問 Bridge。只是把剛才的問題連結過來:就商業端選項而言,現在也逐步回到今天美國的退貨情況,Jamey,我想請你談談你對 Medicare Bridge 的預期——例如 Medicare 的給付是否會在 Bridge 結束後延續;我知道該計畫會在明年年底結束——如果屆時沒有意願更廣泛地提供可近性,你認為在 Medicare 通路內會如何發展?
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Thanks, Kerry. Last question to Jamey around dynamics again on Bridge and also how it's all panning out in the US.
謝謝你,Kerry。最後一題請 Jamey 回答,仍是關於 Bridge 的動態,以及在美國整體進展如何。
Jamey Millar - Executive Vice President of US Operations
Jamey Millar - Executive Vice President of US Operations
Yes, it's difficult to predict what the political environment is going to look like at the end of '27. But as the '28 presidential elections come into play, health care continues to be a dominant topic for US citizens. Family insurance premiums have increased 28% over the last 5 years. So health care costs continued issue for both parties.
是的,很難預測 27 年底的政治環境會是什麼樣子。但隨著 28 年總統大選進入視野,醫療保健仍是美國民眾關注的主導議題。家庭保險保費在過去 5 年上升了 28%。因此醫療成本仍是兩黨共同面臨的議題。
I think as more and more seniors enjoy this coverage for GLP-1s for weight loss that will put pressure politically on continuation of the program. The benefit of this demonstration project is to document eligibility, inclusion, cost and outcomes so that they can make a determination. And obviously, we'll continue to work with the administration, with CMS, with both parties to continue this access opportunity for seniors who are finding it beneficial and affordable.
我認為,隨著愈來愈多長者享有這項針對減重用途 GLP-1 的給付,政治上將會對延續該計畫形成壓力。這個示範計畫的好處在於能記錄資格條件、納入範圍、成本與結果,讓他們得以做出判斷。而且很明顯地,我們會持續與政府、與 CMS、以及兩黨合作,延續這項可近性機會,讓覺得有幫助且負擔得起的長者能繼續使用。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
Great. Thank you very much, Jamey, and thanks, Kerry. So this concludes the Q&A session. And before we ended completely, I also would be remiss even though there's been a lot of thank yous, I also need to say thank you very much to you, Karsten, both from being an analyst on the sell side, and most recently, internally as my direct boss and leader. So thank you very much, and best of luck going forward.
很好。非常感謝你,Jamey,也謝謝你,Kerry。以上為問答環節結束。在完全結束之前,即使已經有很多致謝,我也不能不補上一句:Karsten,我也要非常感謝你——不論是我在賣方擔任分析師時,或最近在公司內部你作為我的直屬主管與領導者。非常感謝,也祝你未來一切順利。
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Karsten Munk Knudsen - Chief Financial Officer, Executive Vice President
Thank you.
謝謝。
Michael Novod - Senior Vice President and Head of Investor Relations
Michael Novod - Senior Vice President and Head of Investor Relations
That was it. Thank you for participating. And feel free to contact Investor Relations regarding any follow-up questions you may have. Thank you very much.
就到這裡。感謝各位參與。如有任何後續問題,歡迎聯絡投資人關係部門。非常感謝。
Operator
Operator
This concludes today's conference call. Thank you for participating. You may now disconnect. Speakers, please stand by.
今天的電話會議到此結束。感謝各位參與。您現在可以掛線。講者請稍候。